Bladder Cancer, Doctor Jewett And ABC discussed on Killer Innovations

Automatic TRANSCRIPT

Bladder cancer is a big problem ten times as many patients with bladder cancer walking around the streets as get it every year. So that captures how chronic diseases. There are a lot of sufferers. The most common type of bladder cancer is confined to the lining of the bladder. And it's called non muscle invasive, bladder cancer, non muscle and bladder cancer is a chronic condition with recurrences with multiple testing multiple treatments. Approximately five percent of patients will ultimately die. If they present with this condition beyond the surgical treatments. There is a drug treatment called CG successful treatment. ABC g would be elimination of either any cancer that was still there after the reception or a durable recurrence, free interval. Generally, something in the range. Thirty forty percent of patients will ultimately become unresponsive after go onto more aggressive treatments. One of those aggressive treatment is removing the bladder the treatment that doctor Jewett and his team are working on would certainly be a welcomed alternative. One of the more innovative approaches to use a combination of light therapy and the drug which sensitisers the cancer cells to that light. So specifically photo sensitisers displaced in the bladder preferentially into the cancer cells and win the follicles are exposed to certain wavelengths of laser light. They will react in the cells have the ultimate outcome is death of those cells. So that is where we get the term photodynamic therapy. Pre clinical studies eventually led to a phase one study that has determined that. The photodynamic therapy is safe in humans. We moved to a fees to study which will be designed to achieve evidence that this works patients assuming that this phase two is positive radicchio this disease. Proportion of those patients, then there is a pretty clear to arriving at a regulatory approval, we recently had a guidance from the FDA which very clearly states, the type of patient, we need to treat and the end points, which are that they're cancer is effectively a radical and that is sustained for a period of a year and affected treatment for g unresponsive patients has been the result of an effective partnership. Has been a wise broker of existing technologies by putting together not only for the sensitisers. That's quite versatile with a different way of delivering laser light where the lighten can be measured. So the total dose calculated to introduce some new safety standard. I think is the unique attractive part of this to me as a practitioner, assuming that we achieve what we're setting out to many solid cancers are going to be treatable with this technology by modulating light wavelength. Different

Coming up next